Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.79 USD | +0.30% | -8.43% | -16.61% |
Financials (USD)
Sales 2024 * | 2.33M | Sales 2025 * | 3.33M | Capitalization | 57.51M |
---|---|---|---|---|---|
Net income 2024 * | -102M | Net income 2025 * | -111M | EV / Sales 2024 * | 24.6 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 17.3 x |
P/E ratio 2024 * |
-0.58
x | P/E ratio 2025 * |
-0.63
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.19% |
Latest transcript on Kezar Life Sciences, Inc.
1 day | +0.30% | ||
1 week | -8.43% | ||
Current month | -12.38% | ||
1 month | -9.28% | ||
3 months | -4.82% | ||
6 months | -17.80% | ||
Current year | -16.61% |
Managers | Title | Age | Since |
---|---|---|---|
Christopher Kirk
FOU | Founder | 52 | 15-02-18 |
John Fowler
FOU | Founder | 52 | 15-02-18 |
Marc Belsky
DFI | Director of Finance/CFO | 68 | 18-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | 16-10-31 |
Graham Cooper
CHM | Chairman | 54 | 17-09-30 |
Michael Kauffman
BRD | Director/Board Member | 60 | 16-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 0.79 | +0.30% | 421,814 |
24-04-18 | 0.7876 | -3.55% | 545,362 |
24-04-17 | 0.8166 | +4.28% | 454,282 |
24-04-16 | 0.7831 | -3.26% | 599,346 |
24-04-15 | 0.8095 | -6.17% | 585,799 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.61% | 57.51M | |
-3.10% | 102B | |
+2.11% | 96.37B | |
-1.80% | 21.37B | |
-17.75% | 20.92B | |
-6.91% | 18.64B | |
-42.00% | 16.4B | |
-28.19% | 13.53B | |
+0.18% | 13.28B | |
+19.90% | 10.85B |
- Stock Market
- Equities
- KZR Stock